Top PCD Pharma Franchise in India: Selection Checklist

Choosing top PCD pharma franchise in India without systematic evaluation is gambling with your business investment. Manufacturers all claim being best. All promise complete support, quality products, exclusive territories, attractive margins.

Then reality arrives three months post-signing.

A structured selection checklist eliminates emotional decision-making and marketing-influenced choices. It forces evaluating every PCD pharma franchise candidate against identical criteria, revealing genuine capability differences hidden behind polished sales presentations.

This checklist covers every evaluation dimension serious pharma franchise entrepreneurs should verify before committing capital and years of business-building effort to any franchise pharma company partnership.

Checklist Section 1: Legal and Regulatory Verification

Start here. Non-negotiable foundation eliminating disqualified candidates immediately.

Manufacturing License Verification

• Drug manufacturing license obtained from state drug control authority

• License currently valid with unexpired dates

• License scope specifically covers product categories you need

• License verified directly through state drug authority—not just manufacturer-provided copies

• No license suspensions or conditions attached

How to verify: Contact issuing state drug control authority directly. Provide license number from manufacturer's copy. Confirm validity, scope, and clean status independently.

Why this matters: Manufacturers with lapsed licenses or licenses not covering your required product categories create immediate regulatory exposure for pharma distributors partnering with them.

WHO-GMP and Schedule M Compliance

• WHO-GMP certificate current and valid

• Certificate specifically covers dosage forms you're distributing

• Schedule M compliance documentation available

• Recent regulatory inspection reports show clean history

• No significant observations from drug control inspections in past 3 years

How to verify: Request certificate copies. Check validity dates. Ask specifically about most recent inspection outcomes. Quality PCD company in India operators share this information readily.

CDSCO Product Approvals

• All products in offered portfolio have valid CDSCO approvals

• Approval status verifiable through CDSCO online database

• No products under import alert or quality recall

• Drug master files current for key products

Products without valid CDSCO approval expose your distribution license to regulatory action regardless of manufacturer's explanations about pending approvals.

Checklist Section 2: Manufacturing Quality Assessment

Regulatory compliance proves minimum standards. Quality assessment reveals actual operational standards.

Facility Evaluation

• Physical facility visit completed (not just virtual tour)

• Manufacturing areas clean, organized, systematically operated

• Equipment modern, well-maintained, properly calibrated

• Separate manufacturing areas for different product categories

• Environmental monitoring systems actively operating

• Documentation current and properly maintained

• Personnel following proper gowning and hygiene protocols

Unannounced visit advantage: Request facility visit within 48 hours notice. Genuine quality manufacturers welcome short-notice visits. Extensive preparation requirements before visits suggest facilities being prepared rather than genuinely shown.

Quality Control Laboratory

• In-house quality control laboratory present and operational

• Testing equipment adequate for claimed testing protocols

• Qualified analytical staff operating laboratory

• Third-party independent testing conducted periodically

• Testing performed on every batch before release

Batch Quality Consistency

• Batch analysis certificates available for 15-20 consecutive recent batches

• Assay results showing tight clustering around label claim

• No wide variation across consecutive batches despite being within specification

• Dissolution testing results documented and consistent

• Stability data available supporting shelf life claims

Request certificates proactively. Top PCD pharma franchise in India quality operators provide them without hesitation. Difficulty obtaining standard documentation reveals quality system gaps.

Checklist Section 3: Product Portfolio Assessment

Quality means nothing if portfolio doesn't match your territory's prescription patterns.

Coverage Completeness

• Portfolio covers primary therapeutic categories your prescribers need

• Multiple formulation options within key categories

• Both premium and value-positioned products in important categories

• New product launches occurring regularly (minimum 8-10 annually)

• Pipeline products addressing emerging market needs

Product-Market Fit

• Products match disease prevalence patterns in your specific territory

• Pricing appropriate for your territory's economic profile

• Formulations suitable for your target prescriber preferences

• Pack sizes matching local prescription patterns

Sample Product Evaluation

• Physical samples obtained and evaluated for quality

• Packaging quality professional and consistent

• Labeling accurate and compliant

• Batch documentation accompanying samples complete

• Sample pricing reasonable (not near-retail pricing)

Checklist Section 4: Territory Rights Verification

Territory protection determines your long-term competitive position. Verify precisely.

Exclusivity Scope

• Territory boundaries defined by specific geographic parameters (pin codes, districts)

• Exclusivity scope clearly written in agreement—not verbal assurance

• Online sales within your territory explicitly addressed

• Institutional supply coverage within territory defined

• Government tender supply rights clarified

• Direct doctor supply restrictions within territory specified

PCD pharma franchise monopoly basis arrangements vary enormously in actual protection provided. "Exclusive territory" with broad exceptions for institutional, online, and key accounts may provide minimal real protection. Understand precisely what's actually exclusive.

Existing Partner Verification

• List of existing partners in surrounding territories obtained

• No existing partners already operating within your proposed territory

• Adequate buffer distance between your territory and nearest existing partner

• Company policy on minimum partner spacing understood

Violation Remedies

• Agreement specifies investigation obligation when violations reported

• Resolution timeline for territory disputes documented

• Compensation mechanism for genuine territory violations included

• Escalation process for unresolved violations specified

Checklist Section 5: Support System Reality

Every franchise pharma company promises complete support. This checklist section tests whether promises reflect operational reality.

Field Support Verification

• Specific field visit frequency committed in writing (not verbal promise)

• Named regional manager responsible for your territory identified

• Field staff visit history with existing partners in similar territories verified

• Emergency support availability for urgent issues confirmed

Verification method: Ask for contact details of 5 existing partners in territories similar to yours. Find additional partners independently through LinkedIn. Ask specifically: "How frequently does field staff actually visit your territory?"

Training Programs

• Initial product training program content reviewed

• Ongoing training frequency and format confirmed

• Scientific information support for clinical prescriber questions available

• Sales technique training included beyond product knowledge

Marketing Materials

• Visual aid samples reviewed for quality and clinical accuracy

• Promotional material update frequency confirmed

• Digital marketing support availability assessed

• Marketing material customization options explored

Communication Standards

• Primary contact person identified with direct contact details

• Backup contact for primary contact unavailability established

• Response time commitment for routine queries obtained

• Escalation path for unresolved issues documented

Test communication during evaluation phase. Send specific detailed questions via email and WhatsApp. Measure actual response times. How companies communicate before signing predicts how they'll communicate after.

Checklist Section 6: Financial Terms Assessment

Financial sustainability depends on complete terms understanding, not just headline margins.

Margin and Pricing

• Complete price list for full product range obtained

• Distributor margins calculated across key products

• MRP versus distributor price spread verified for each product

• Scheme structure for volume incentives fully understood

• Price revision history over past 24 months reviewed

Payment Terms

• Initial payment terms clearly specified (advance vs credit)

• Credit terms available after relationship establishment confirmed

• Minimum order quantities per product and per order specified

• Return policy for slow-moving and near-expiry products documented

Hidden Cost Identification

• Sample product pricing at promotional versus regular rates confirmed

• Marketing material charges versus free provision clarified

• Freight and delivery charges on orders specified

• Any registration or franchise fees clearly identified

• Annual renewal costs or ongoing fees disclosed

Checklist Section 7: Independent Reference Verification

Manufacturer-provided information requires independent corroboration.

Existing Partner Research

• Minimum 5 existing partners contacted independently (not manufacturer references)

• Partners found through LinkedIn or industry networks, not manufacturer lists

• Specific questions about stock-out frequency asked and answered

• Quality complaint handling experience described specifically

• Support reality versus promises assessed from multiple independent sources

• Whether they would re-sign knowing what they know now asked directly

Prescriber Intelligence

• Target territory prescribers asked about manufacturer brand familiarity

• Previous prescriber experience with manufacturer's products assessed

• Clinical reputation of manufacturer among territory doctors evaluated

Industry Reputation Research

• Pharmaceutical distributor associations consulted about manufacturer reputation

• Trade exhibition contacts asked about industry standing

• Any known regulatory actions or industry disputes investigated

Checklist Section 8: Agreement Review

Before signing any PCD pharma franchise agreement, verify these elements explicitly.

Critical Agreement Elements

• Territory boundaries precisely defined with geographic specifics

• Exclusivity scope and exceptions completely listed

• New product right of first refusal included

• Price revision notice period minimum 30 days specified

• Supply failure remedies documented

• Termination notice period minimum 60 days required

• Post-termination inventory repurchase obligation included

• Cure periods before termination for performance issues specified

• Dispute resolution mechanism clearly defined

Professional Review

• Agreement reviewed by qualified legal professional

• All verbal promises reflected in written agreement

• Ambiguous language clarified before signing

• No unilateral amendment rights given to manufacturer

Legal review costs ₹5,000-15,000. It protects years of territory investment and business-building effort. Non-negotiable for serious PCD company in India partnerships.

Using This Checklist Effectively

Print this checklist. Work through every item systematically for each top pcd pharma franchise in India candidate you're evaluating.

Items you cannot complete—because manufacturer refuses information, documentation is unavailable, or verification proves impossible—are themselves evaluation results. Genuine quality operators welcome thorough evaluation because clean records and honest operations benefit from scrutiny.

Score each candidate across sections. Compare scores systematically rather than relying on overall impressions formed during enthusiastic sales presentations.

Pharma distributors who complete thorough evaluation before committing consistently build more successful partnerships than those rushing into agreements based on pricing alone or marketing impressions. The checklist investment takes time upfront. It saves years of frustration, capital losses, and missed opportunity from wrong partner selection.

Read more: Territory Coverage Strategy for Derma PCD Company in India Success